A Double-blind, Randomised, Placebo-controlled Study to Determine the Safety, Pharmacokinetics and Maximum Tolerated Dose of NRP2945 In Healthy Adult Volunteers.
Phase of Trial: Phase I
Latest Information Update: 28 Nov 2017
At a glance
- Drugs NRP 2945 (Primary)
- Indications Epilepsy
- Focus Adverse reactions
- Sponsors CuroNZ
- 28 Nov 2017 Status changed from recruiting to completed, as per the communication received from Dr Frank Sieg, Chief Scientific Officer of CuroNZ.
- 22 Mar 2017 Status changed from not yet recruiting to recruiting.
- 14 Mar 2017 New trial record